Viewpoints
Opinion

Reviving AstraZeneca’s Stocks Is a Matter of Confidence

Google LogoMark Us Preferred on Google
Reviving AstraZeneca’s Stocks Is a Matter of Confidence
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken on March 14, 2021. Dado Ruvic/Illustration/Reuters
Gabriël Moens
|Updated:
Commentary

Australian chief medical officers have embarked on a campaign to rehabilitate the AstraZeneca vaccine as a suitable COVID-19 jab.

Google LogoMark Us Preferred on Google
Gabriël Moens
Gabriël Moens
Author
Gabriël A. Moens AM is an emeritus professor of law at the University of Queensland, and served as pro vice-chancellor and dean at Murdoch University. In 2003, Moens was awarded the Australian Centenary Medal by the prime minister for services to education. He has taught extensively across Australia, Asia, Europe, and the United States.
Related Topics